Rayner has announced it has acquired the United States distribution rights to Anikavisc, the ophthalmic viscosurgical device (OVD), from Visco Technologies Inc - a move that strengthens the company’s US cataract ecosystem and advances its mission to deliver a truly comprehensive portfolio of solutions.
Anikavisc OVD is used intraoperatively to protect the corneal endothelium, maintain anterior chamber depth and enable controlled surgical manipulation. The cohesive formula is designed to deliver consistent performance and surgical efficiency.
The acquisition comes at a pivotal moment for Rayner, as the company celebrates the US launch of its FDA-approved Sophi phaco platform and continues to expand access to its portfolio, including the RayOne EMV Toric IOL. With the PMA submission for RayOne Galaxy — the world’s first AI-designed spiral IOL - now complete, Rayner is positioning itself to offer a comprehensive, bundle-ready portfolio in 2026 - spanning premium and monofocal IOLs, OVD and advanced phaco technology.
“We’re excited about what this acquisition means for our US customers,” said Scott Corning, Vice President Americas at Rayner. “Anikavisc customers will see no changes to their current arrangements, but its reach and support will grow through our direct sales team from today. This also allows us to offer a fully bundled cataract solution, simplifying orders and streamlining purchasing, and delivers even greater value through one dedicated partner committed to innovation in cataract surgery.”
